Baillie Gifford & Co. boosted its position in shares of Beigene Ltd (NASDAQ:BGNE) by 15.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 94,716 shares of the company’s stock after buying an additional 12,938 shares during the quarter. Baillie Gifford & Co.’s holdings in Beigene were worth $13,285,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Northern Trust Corp raised its stake in shares of Beigene by 25.2% in the second quarter. Northern Trust Corp now owns 2,250 shares of the company’s stock worth $346,000 after purchasing an additional 453 shares during the last quarter. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Beigene in the third quarter worth approximately $2,119,000. JPMorgan Chase & Co. raised its stake in shares of Beigene by 65.5% in the third quarter. JPMorgan Chase & Co. now owns 59,384 shares of the company’s stock worth $10,226,000 after purchasing an additional 23,495 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Beigene by 14.2% in the third quarter. Alliancebernstein L.P. now owns 279,330 shares of the company’s stock worth $48,106,000 after purchasing an additional 34,750 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Beigene by 14.1% in the third quarter. Janus Henderson Group PLC now owns 442,507 shares of the company’s stock worth $76,208,000 after purchasing an additional 54,593 shares during the last quarter. Institutional investors own 79.69% of the company’s stock.
In other Beigene news, CEO John Oyler sold 4,588 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $152.01, for a total transaction of $697,421.88. Following the completion of the transaction, the chief executive officer now directly owns 17,298,245 shares of the company’s stock, valued at $2,629,506,222.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CMO Amy C. Peterson sold 20,000 shares of the stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $133.68, for a total value of $2,673,600.00. Following the transaction, the chief marketing officer now directly owns 194,569 shares of the company’s stock, valued at $26,009,983.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,794 shares of company stock valued at $8,327,479. 13.30% of the stock is currently owned by corporate insiders.
BGNE has been the subject of several analyst reports. Maxim Group set a $170.00 price objective on Beigene and gave the stock a “buy” rating in a research note on Tuesday, November 27th. Piper Jaffray Companies set a $200.00 target price on Beigene and gave the company a “buy” rating in a report on Sunday, December 2nd. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a report on Friday, November 30th. Zacks Investment Research raised Beigene from a “hold” rating to a “buy” rating and set a $147.00 target price for the company in a report on Tuesday, January 8th. Finally, ValuEngine lowered Beigene from a “strong-buy” rating to a “buy” rating in a report on Friday, February 15th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $177.68.
BGNE stock opened at $134.78 on Friday. The company has a market capitalization of $8.08 billion, a PE ratio of -11.09 and a beta of 1.20. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.89 and a quick ratio of 7.82. Beigene Ltd has a 12-month low of $105.19 and a 12-month high of $220.10.
Beigene (NASDAQ:BGNE) last released its earnings results on Wednesday, February 27th. The company reported ($4.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($1.97). The business had revenue of $58.67 million during the quarter, compared to the consensus estimate of $59.37 million. Beigene had a negative net margin of 339.91% and a negative return on equity of 42.63%. The business’s revenue was up 222.8% on a year-over-year basis. During the same period in the prior year, the company earned ($2.19) earnings per share. Analysts anticipate that Beigene Ltd will post -13.85 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thelincolnianonline.com/2019/03/15/baillie-gifford-co-has-13-29-million-position-in-beigene-ltd-bgne.html.
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Recommended Story: Cost of Capital Explained
Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beigene Ltd (NASDAQ:BGNE).
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.